Feature | March 16, 2015

Survival Rates Improve for Heart Failure Patients with CardioMEMS HF System

Patients with reduced ejection fraction experience significant reductions in mortality, hospitalizations during CHAMPION trial

St. Jude, CardioMEMS, CHAMPION trial, heart failure, reduced ejection fraction

The CardioMEMS device is implanted in the pulmonary artery via a short, femoral vein access cath procedure. It measures changes in pulmonary artery pressure, which are a surrogate measure for fluid retention in the lungs due to worsening heart failure conditions. The device is unique in that it does does not use a battery.

March 16, 2015 — Heart failure (HF) patients with reduced ejection fraction experienced significant HF mortality and hospitalization reductions via guideline-directed medical therapy managed by pulmonary artery (PA) pressure monitoring using the CardioMEMS HF System, according to a data analysis from the CHAMPION trial. This new retrospective data analysis was presented during the American College of Cardiology (ACC) 2015 Annual Scientific Sessions.

According to the results, patients using the CardioMEMS system had a 57 percent reduction in mortality and a 43 percent reduction in HF hospitalizations compared with patients on guideline determined medical therapy managed by the standard of care.

The analysis looked at patients with HF and reduced ejection fraction (HFrEF) over an average of 17 months who were on optimal GDMT and compared those managed by PA pressure monitoring with the CardioMEMS HF System to those managed by SOC. The CHAMPION trial retrospective analysis demonstrated that PA pressure monitoring, in addition to GDMT, significantly reduced HF hospitalizations and mortality in patients with reduced ejection fraction.

“For heart failure patients whose heart does not contract effectively, the risk for hospitalization and mortality is very high, even with appropriate evidence-based medical therapy. The findings from this analysis show us that use of the CardioMEMS HF System in addition to guideline directed medical therapy can significantly reduce hospital admissions for these heart failure patients and for the first time, we also see a significant improvement in survival,” said William Abraham, M.D., chief of cardiovascular medicine at The Ohio State University Wexner Medical Center and presenter of these data.

View a video interview at ACC 2015 with the Abraham on the CHAMPION DATA and his experience with CardioMEMS.

The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery during a minimally invasive procedure to directly measure PA pressure. PA pressure allows clinicians to proactively manage treatment for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur. The system allows patients to transmit PA pressure data from their homes to their healthcare providers, who then manage appropriate medication changes to reduce the likelihood of hospitalization and improve survival.

The CHAMPION trial evaluated the overall safety and effectiveness of the CardioMEMS device for New York Heart Association (NYHA) Class III HF patients who had been hospitalized for HF in the previous 12 months. The CHAMPION trial demonstrated a 37 percent reduction in HF hospitalizations during an average follow-up duration of 15 months.

For more information: www.sjm.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init